Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.
Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.
In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.
Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.
Boston Scientific (NYSE: BSX) will webcast a conference call to discuss its first quarter ended March 31, 2026 results on April 22, 2026 at 8:00 a.m. ET.
The call will be hosted by Mike Mahoney, chairman and CEO, and Jon Monson, EVP and CFO. A news release with results will be issued before the call; live webcast and replay available at the company's investor site.
Boston Scientific (NYSE: BSX) received FDA 510(k) clearance on March 30, 2026 for the Asurys Fluid Management System, an irrigation and distention system for endoscopic urologic procedures. The device pairs with LithoVue Elite to help monitor and regulate intrarenal pressure (IRP). A limited U.S. market release will begin in the coming days.
The system is intended for ureteroscopy, cystoscopy, percutaneous nephrolithotomy (PCNL) and BPH procedures and is part of the StoneSmart ecosystem.
Boston Scientific (NYSE: BSX) announced that the CHAMPION-AF trial of the WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints at 36 months. The randomized trial enrolled 3,000 NVAF patients and showed reduced bleeding and non-inferior efficacy versus NOACs.
Key metrics: non-procedural major and clinically relevant non-major bleeding 10.9% vs 19.0% (45% relative reduction), combined procedural+non-procedural bleeding 12.8% vs 19.0% (34% reduction), efficacy composite 5.7% vs 4.8% (non-inferior), 99% procedural success, ongoing follow-up to five years.
Boston Scientific (NYSE: BSX) reported that the randomized HI-PEITHO trial met its primary endpoint: EKOS plus anticoagulation was superior to anticoagulation alone for intermediate-risk pulmonary embolism (4.0% vs. 10.3%; P=0.005), a 61% relative reduction in events.
Trial enrolled 544 patients across 59 U.S. and European sites; no intracranial bleeding through 30 days; patients will be followed to one year.
Summary not available.
Boston Scientific (NYSE: BSX) will host an investor event and live webcast on March 28, 2026 at 6:30 p.m. ET / 5:30 p.m. CT to discuss key clinical data presented at the 75th Annual Scientific Session of the American College of Cardiology.
The event will feature Dr. Kenneth Stein, Dr. Brad Sutton, and Dr. Michael R. Jaff. The live webcast and replay will be accessible at https://investors.bostonscientific.com, with replay available about one hour after the event ends.
Penumbra (NYSE: PEN) reported fourth-quarter 2025 revenue of $385.4M (+22.1%) and full-year 2025 revenue of $1,403.7M (+17.5%). Gross margin improved to 68.0% in Q4 and 67.1% for FY2025. Income from operations was $59.2M in Q4 and $189.2M for FY2025. Net income for Q4 was $47.3M and FY net income was $177.7M. The company will not provide 2026 guidance or host an earnings call due to the proposed acquisition by Boston Scientific (NYSE: BSX).
Boston Scientific (NYSE: BSX) elected Cathy Smith and Christophe Weber to its Board of Directors, effective Feb 18, 2026.
Smith brings senior finance and operational experience as current CFO of Starbucks and former CFO roles at major retailers; Weber adds global pharmaceutical and CEO leadership from Takeda. Their elections follow announced retirements of John Sununu and Yoshiaki Fujimori, who will not stand for re-election at the 2026 annual meeting.
Boston Scientific (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and CEO, and Kenneth Stein, M.D., senior VP and global chief medical officer, will join a 30-minute Q&A at ~9:10 a.m. ET.
A live webcast and replay will be available at the company investor website, with the replay posted about one hour after the session ends.
Boston Scientific (NYSE: BSX) reported strong fourth-quarter 2025 results with Q4 net sales of $5.286 billion (+15.9% reported, +12.7% organic) and GAAP EPS of $0.45 (adjusted EPS $0.80). For full-year 2025, net sales were $20.074 billion (+19.9% reported) and adjusted EPS was $3.06. The company provided 2026 guidance of ~10.5–11.5% reported net sales growth and adjusted EPS of $3.43–3.49. Key developments include FDA/CE approvals for FARAPOINT PFA catheter, launches of SEISMIQ IVL and TheraSphere 360 clearance, enrollment and trial progress across AF, SCS and LAA closure studies, announced acquisitions of Penumbra and Valencia Technologies, and completion of the Nalu Medical acquisition.